In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite control and metabolic pathways, with pharmaceutical ...

The Obesity Gurukul initiative will train over 20,000 healthcare professionals across India through a hybrid education model ...

The initiative will provide practical insights into understanding of obesity pathophysiology and its management.

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Mumbai: Mumbai-based pharma giant Cipla is gearing up to make an entry into India's rapidly growing weight management market, ...

If every pharma company had this, they would have much greater access to their medications without people in the middle." In ...

The pharma major is also strengthening its presence in the central nervous system (CNS) therapeutic area, Vohra stated ...

Cipla Limited is planning to enter the weight management segment in India, announced the company’s MD and global CEO Umang ...

The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...